Glyburide (10238-21-8) is a second generation oral hypoglycemic agent. Acts via ATP-dependent K+ channel (Kir6, KATP) block.1 Inhibits Kir6 currents in the pancreas, causing an increase in intracellular Ca2+ and insulin secretion. Glyburide also inhibits recombinant CFTR Cl- channels with an IC50 of 20 μM.2 Cell permeable.
1) Brogden et al. (1979), Glipizide: a review of its pharmacological properties and therapeutic use; Drugs, 18 329
2) Sheppard and Welsh (1992), Effect of ATP-sensitive K+ channel regulators on cystic fibrose transmembrane conductance regulator chloride currents; J. Gen. Physiol., 100 573